EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.

Purpose: More than 90% of Ewing's sarcomas (ES) contain a fusion of the EWS and FLI1 genes, due to the t(11;22)(q24;q12) translocation. At the molecular level, the EWS-FLI1 rearrangements show great diversity. Specifically, many different combinations of exons from EWS and FLI1 encode in-frame fusio...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Oncology Vol. 16; no. 4; pp. 1248 - 1256
Autores principales: de Alava, Enrique, Kawai, Akira, Healey, John H., Fligman, Igal, Meyers, Paul A., Huvos, Andrew G., Gerald, William L., Jhanwar, Suresh C., Argani, Pedram, Antonescu, Cristina R., Pardo-Mindan, F. Javier, Ginsberg, Jill, Womer, Richard, Lawlor, Elizabeth R., Wunder, Jay, Andrulis, Irene, Sorensen, Poul H. B., Barr, Frederic G., Ladanyi, Marc, de Alava, E
Formato: research Journal Article
Publicado: American Society of Clinical Oncology Apr1998
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=88362897&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 88362897
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        0732183X
        20D
      jtl: Journal of Clinical Oncology
      issn: 0732183X
      maglogo: N
    pubinfo:
      dt: Apr1998
      vid: 16
      iid: 4
      pid: 26892
      pub: American Society of Clinical Oncology
      place: Alexandria, Virginia
    artinfo:
      ui:
        88362897
        88362897
        NLM9552022
        88362897
        NLM9552022
        88362897
      ppf: 1248
      ppct: 8
      formats:
      tig:
        atl: EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.
      aug:
        au:
          de Alava, Enrique
          Kawai, Akira
          Healey, John H.
          Fligman, Igal
          Meyers, Paul A.
          Huvos, Andrew G.
          Gerald, William L.
          Jhanwar, Suresh C.
          Argani, Pedram
          Antonescu, Cristina R.
          Pardo-Mindan, F. Javier
          Ginsberg, Jill
          Womer, Richard
          Lawlor, Elizabeth R.
          Wunder, Jay
          Andrulis, Irene
          Sorensen, Poul H. B.
          Barr, Frederic G.
          Ladanyi, Marc
          de Alava, E
        affil: Clinica Universitaria de Navarra, Pamplona, Spain
      sug:
        subj:
          Bone Neoplasms Drug Therapy
          Proteins
          Osteosarcoma Drug Therapy
          Antineoplastic Agents, Combined Therapeutic Use
          Bone Neoplasms
          Male
          Osteosarcoma
          Human
          Bone Neoplasms Mortality
          Osteosarcoma Mortality
          Adult
          Multivariate Analysis
          Female
          Genes
          Prognosis
          Proteins Classification
          Survival Analysis
          Polymerase Chain Reaction
          Adolescence
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Clinical Assessment Tools
          Scales
          Adult: 19-44 years
          Adolescent: 13-18 years
          Male
          Female
      ab: Purpose: More than 90% of Ewing's sarcomas (ES) contain a fusion of the EWS and FLI1 genes, due to the t(11;22)(q24;q12) translocation. At the molecular level, the EWS-FLI1 rearrangements show great diversity. Specifically, many different combinations of exons from EWS and FLI1 encode in-frame fusion transcripts and result in differences in the length and composition of the chimeric protein, which functions as an oncogenic aberrant transcription factor. In the most common fusion type (type 1), EWS exon 7 is linked in frame with exon 6 of FLI1. As the fundamental pathogenetic lesion in ES, the molecular heterogeneity of these fusion transcripts may have functional and clinical significance. Patients and Methods: We performed a clinical and pathologic analysis of 112 patients with ES in which EWS-FLI1 fusion transcripts were identified by reverse-transcriptase polymerase chain reaction (RT-PCR). Adequate treatment and follow-up data were available in 99 patients treated with curative intent. Median follow-up in these 99 patients was 26 months (range, 1 to 140 months). Univariate and multivariate survival analyses were performed that included other prognostic factors, such as age, tumor location, size, and stage. Results: Among the 99 patients suitable for survival analysis, the tumors in 64 patients contained the type 1 fusion and in 35 patients contained less common fusion types. Stage at presentation was localized in 74 patients and metastatic in 25. Metastases (relative risk [RR] = 2.6; P = .008), and type 1 EWS-FLI1 fusion (RR = 0.37; P = .014) were, respectively, independent negative and positive prognostic factors for overall survival by multivariate analysis. Among 74 patients with localized tumors, the type 1 EWS-FLI1 fusion was also a significant positive predictor of overall survival (RR = 0.32; P = .034) by multivariate analysis. Conclusion: EWS-FLI1 fusion type appears to be prognostically relevant in ES, independent of tumor site, stage, and size. Further studies are needed to clarify the biologic basis of this phenomenon.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N